Nektar Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $11,790 | $11,175 | $10,460 | $29,175 |
Gross Profit | 11,790 | 11,175 | 10,460 | 21,198 |
EBITDA | -29,312 | -33,787 | -40,969 | 17,487 |
EBIT | -29,508 | -34,001 | -41,395 | 17,155 |
Net Income | -35,522 | -41,593 | -50,882 | 7,261 |
Net Change In Cash | 11,790 | 11,175 | 10,460 | 29,175 |
Free Cash Flow | -48,875 | -45,775 | -49,055 | -46,646 |
Cash | 41,032 | 42,988 | 38,894 | 44,252 |
Basic Shares | 14,087 | 14,087 | 14,061 | 14,239 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $98,427 | $90,122 | $92,055 | $101,907 |
Gross Profit | 67,741 | 53,478 | 70,420 | 77,010 |
EBITDA | -86,697 | -243,107 | -323,872 | -461,821 |
EBIT | -91,088 | -250,922 | -336,072 | -475,967 |
Net Income | -118,961 | -276,056 | -368,198 | -523,837 |
Net Change In Cash | 98,427 | 90,122 | 92,055 | 101,907 |
Cost of Revenue | -173,645 | |||
Free Cash Flow | -177,177 | -193,471 | -309,683 | -427,649 |
Cash | 44,252 | 35,277 | 88,227 | 25,218 |
Basic Shares | 13,710 | 12,666 | 12,475 | 12,219 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$1.87 |
2025-06-30 | -$2.95 |
2025-03-31 | -$0.24 |
2024-12-31 | -$0.15 |
